The Burden of Short-Acting β₂-Agonist Use in Asthma: Is There an Italian Case? An Update from SABINA Program.

ABSTRACT:

Introduction

Preliminary results from the SABINA (SABA use IN Asthma) program showed lower overuse of short-acting β₂-agonist (SABA) in Italy compared to other European countries. The aim of the present study was to ascertain whether SABINA's results might have been affected by the Italian National Health System and pharmaceutical market dynamics, by examining patients' characteristics in relation to SABA prescription/purchase habits.

Methods

Multiple approaches were used: (1) a retrospective study using the General Practitioners' (GPs) Italian IQVIA Longitudinal Patient Database (LPD) to assess SABA overuse (more than two canisters/year) and its association with exacerbation risk; (2) a survey conducted across 200 Italian pharmacies to calculate the proportions o

SUBMITTER: Di Marco F 

PROVIDER: S-EPMC8280008 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature